See What HealthDay Can Do For You
Contact Us

ADA: New Drugs Show Promise for Type 2 Diabetes

Studies demonstrate the safety and efficacy of liraglutide and aleglitazar

TUESDAY, June 9 (HealthDay News) -- In patients with type 2 diabetes, once-daily liraglutide may be superior to twice-daily exenatide, and the investigational drug aleglitazar may be superior to pioglitazone, according to two studies published online June 8 in The Lancet to coincide with presentations at the American Diabetes Association's 69th Scientific Sessions, held from June 5 to 9 in New Orleans.

In one study, John B. Buse, M.D., of the University of North Carolina School of Medicine in Chapel Hill, and colleagues assigned 464 adults whose diabetes was inadequately controlled with the maximum tolerated doses of metformin, sulphonylurea, or both, to supplemental once-daily liraglutide or twice-daily exenatide. They found that liraglutide was associated with a greater mean reduction of HbA1C level and a higher rate of patients achieving a level below 7 percent.

In a second study, Robert R. Henry, M.D., of the University of California in San Diego, and colleagues assigned 332 patients to once-daily aleglitazar at varying doses or matching placebo, or once daily pioglitazone at a dose of 45 micrograms. After 16 weeks, they found that aleglitazar was associated with dose-dependent reductions of HbA1c ranging from 0.36 percent to 1.35 percent. They also found no association with heart failure in doses less than 300 micrograms, and only one case of edema; and that aleglitazar at a dose of 150 micrograms resulted in less than half the weight gain as pioglitazone.

"The favorable balance in the safety and efficacy profile of aleglitazar represents encouraging short-term clinical data for this agent and provides good evidence to enter phase III investigation," Henry and colleagues write.

The first study was supported by Novo Nordisk, and one author reported a financial relationship with the company. The second study was supported by F. Hoffmann-La Roche, and two authors reported financial relationships with the company.

Abstract - Buse
Full Text (subscription or payment may be required)
Abstract - Henry
Full Text (subscription or payment may be required)
More Information (American Diabetes Association)

Physician's Briefing
undefined
undefinedundefined